2Marx UC,Alderman K,Bayer P,et al.Solution structures of human parathyroid hormone fragments hPTH(1-34) and hPTH(1-39) and bovine parathyroid hormone fragments bPTH (1-37).Biochem Biophys Res Commun,2000,267 (1):213-220.
6Robert M,Arnaud CD,Zanchetla JR,et al.Effect of parathyroid hormone (1-34)on fractures and bone mineral density in postmenopausal woman with osteoporosis.Med,2001,344 (19):1434-1440.
7Kitahara K,Muneaki I.Osteopontin deficency induces parathyroid hormone enhancement of cortical bone formation.Endocri Nology,2003,144(5):2132-2139.
8Divieti P,John MR,Juppner H,et al.Human PTH (7-84)inhibits bone resorption in vitro via actions independent of the type Ⅰ PTH/PTHrPreceptor.Endocri Nology,2002,143 (1):171-175.
9Ma YL,Cain RI,Halladay DL,et al.Catabolic effects of continuous human PTH (1-38)in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation.Endocrinology,2001,142:4047-4054.
6Morley P, Whitfield F, WiUick E. Anabolic effects of parathyroid hormone on bone[J]. Tzends Endocrinol Metab,1997,8: 225-231.
7Mannstadt M, Jüppner H, Gardella J. Receptors for PTH and PTHrP: their biological importance and functional properties[J]. Am J Physiol, 1999,277 (Renal Physiol 46):665-675.
8Friedlander G, Amiel C. Cellular mode of action of parathyroid hormone [J]. Adr Nephrol Necker Hosp, 1994, 23: 265-279.
9Zull J E, Smith S K, Wiltshire R. Effect of methionine oxidation and deletion of amino-terminal residues on the conformation of parathyroid hormone[J]. J Biol Chem, 1990, 265(10) : 5671-5676.
10Marx U C, Alderman K, Bayer P, et al. Solution structures of human parathyroid hormone fragments hPTH (1-34) and hPTH(1-39) and bovine parathyroid hormone fragment bPTH(1-37)[-J]. Biochem Biophys Res Commun, 2000,267 (1): 213-220.
7Altman R,Asch E, Bloch D, et al. Development of criteria for theclassification and reporting of osteoarthritis: classification of OS-teoarthritis of the knee [J]. Arthritis Rheum, 1986,29 ( 8 ) : 1039-1049.
8Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee [J]. Rheumatol,1988,15(12):1833-1840.
9Glowaeki J, Hurwitz S, Thornhill TS,et al. Osteoporosis and vitamin-D deficiency among postmenopausal women with osteoarthritis undergoing total hip arthroplasty[J]. Bone Joint Surg Am, 2003,85-A(12): 2371-2377.
10Corrado A, Cantatore FP, Grano M, et al. Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects[J]. Clin Rheumatol, 2005,24(5) : 527-534.
